格隆汇12月16日丨艾隆科技(688329.SH)公布，公司于2025年12月16日收到徐立先生出具的《减持计划 时间届满暨减持股份结果的告知函》。徐立先生在2025年9月16日至2025年12月15日期间通过集中竞 价、大宗交易方式累计减持公司股份27.71万股，所持有的公司股份数量由845.8万股减少至818.09万 股，占公司总股本的比例由10.96%减少至10.60%，本次减持计划时间已届满。 ...

证券代码：688329 证券简称：艾隆科技 公告编号：2025-057 苏州艾隆科技股份有限公司 关于持股 5%以上股东减持计划时间届满 暨减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东及董监高持有的基本情况 本次减持计划实施前，苏州艾隆科技股份有限公司（以下简称"公司"）董 事长兼总经理徐立先生持有公司股份 8,458,000 股，占公司总股本的 10.96%， 其中 8,457,500 股为公司首次公开发行前取得的股份，已于 2024 年 4 月 10 日解 除限售并上市流通，500 股通过集中竞价交易方式取得。 减持计划的实施结果情况 公司于 2025 年 8 月 25 日在上海证券交易所网站（www.sse.com.cn）披露了 《艾隆科技股东及董监高减持股份计划公告》（公告编号：2025-040），因自身资 金需求，徐立先生拟通过集中竞价或大宗交易方式减持所持有公司股份合计不超 过 300,000 股，占公司总股本的 0.39%。其中，在任意连续 90 日内， ...

艾隆科技公告，董事长兼总经理徐立在2025年9月16日至2025年12月15日期间通过集中竞价、大宗交易 方式累计减持公司股份27.71万股，占公司总股本的0.36%。减持价格区间为19.8～22.9元/股，减持总金 额为581.84万元。减持后，徐立所持公司股份数量由845.8万股减少至818.09万股，占公司总股本的比例 由10.96%减少至10.60%。 ...

Summary of Key Points from Conference Call Records Industry Overview - The Chinese smart hospital industry is transitioning from a tool revolution to an ecological revolution driven by AI technology, which enhances medical service intelligence but faces challenges such as data acquisition difficulties and regional application imbalances [1][4] - The global smart hospital industry relies on deep penetration of AI technology to empower the healthcare sector, aiming to improve diagnostic efficiency and service quality while addressing resource shortages and aging populations [2] Core Insights and Arguments - AI large models have restructured the traditional AI medical framework, evolving from a simple structure to a multi-modal era that integrates various data types for comprehensive medical assistance [1][6] - The penetration rates of AI applications in economically developed regions significantly exceed those in less developed areas, with outpatient dispensing machines at 57.18% in developed regions compared to 28.38% in moderately developed regions [4] - The automated pharmacy market in China is projected to grow from 196.7 billion yuan in 2022 to 458 billion yuan by 2027, driven by new healthcare infrastructure policies and the pursuit of operational efficiency [13][14] Market Dynamics - The automated pharmacy market is segmented into hospital end, chain pharmacies, and centralized compounding centers, with the hospital end being the core segment, expected to reach 319.69 billion yuan by 2027 [15] - The penetration rates of automated pharmacies vary significantly across hospital tiers, with tertiary hospitals expected to reach 65% penetration by 2027, while secondary and primary hospitals lag behind [16] Competitive Landscape - The hospital information technology sector is highly competitive, with companies like Weining Health and Yilianzhong leading the market, focusing on various core areas such as HIS systems and public health management [17] - In the automated pharmacy sector, companies like Jianhui Information and Ailong Technology dominate, leveraging comprehensive coverage and customized solutions to maintain competitive advantages [18] Challenges and Opportunities - The smart hospital industry faces challenges in acquiring standardized and structured data, which remains a core pain point [2][4] - Despite a decline in overall investment enthusiasm since 2022, the AI healthcare sector continues to attract significant capital, indicating a focus on actual profitability and technological implementation [5] Additional Insights - Self-service terminals in hospitals have high usage rates for functions like report printing (84%) and payment (82.3%), significantly improving patient experience and operational efficiency [9] - Smart medical record management enhances service efficiency by digitizing traditional paper records, reducing resource consumption and improving data accessibility [11] Future Directions - The automated pharmacy industry is expected to evolve towards standardization and intelligence, with companies focusing on product innovation and expanding channel systems to maintain market share [19][20]

Group 1 - The core viewpoint of the news is that Ailong Technology (688329) has shown a significant increase in revenue and net profit in the third quarter of 2025, indicating positive growth despite a net loss in the first three quarters [2] - Ailong Technology's main business focuses on intelligent management of medical supplies, providing comprehensive solutions through smart management devices and software platforms for healthcare institutions [2] - The company's revenue for the first three quarters of 2025 reached 280 million yuan, a year-on-year increase of 25.12%, while the net profit attributable to shareholders was a loss of 959,000 yuan, but this represented a year-on-year improvement of 96.56% [2] Group 2 - In the third quarter of 2025, Ailong Technology reported a single-quarter revenue of 149 million yuan, which is an 83.53% year-on-year increase, and a net profit of 7.43 million yuan, reflecting a year-on-year increase of 182.09% [2] - The company's debt ratio stands at 42.74%, with investment income recorded at a loss of 4.25 million yuan and financial expenses amounting to 4.69 million yuan, while the gross profit margin is 45.79% [2] - The capital flow data on December 9, 2025, indicates a net outflow of 987,800 yuan from main funds, accounting for 6.33% of the total transaction amount, while retail funds saw a net inflow of 1.81 million yuan, representing 11.61% of the total transaction amount [1]

Investment Rating - The report does not explicitly state an investment rating for the smart hospital industry in China Core Insights - The smart hospital industry in China is transitioning from a tool revolution to an ecosystem revolution, with companies like Weining Health and Donghua Software competing in the digital hospital solution market [1] - The AI healthcare ecosystem is supported by infrastructure development and data collection, enhancing diagnostic efficiency and service quality to address issues like resource shortages and aging populations [4] - Despite a slowdown in overall healthcare investment since 2022 due to geopolitical tensions and more realistic technology expectations, the "AI + healthcare" sector continues to attract significant investment driven by demand and technology [4][10] Summary by Sections Research Purpose and Overview - The report aims to explore the market hotspots, sub-industry conditions, and competitive landscape of the smart hospital industry in China [2][3] Global and Chinese Smart Hospital Industry Development - The global smart hospital industry is experiencing rapid advancements in AI technology, leading to a shift towards intelligent, digital, and information-driven healthcare [5] - The Chinese smart hospital industry is characterized by a diverse range of players and significant potential for growth, particularly in AI integration and digital infrastructure [24] AI Healthcare Investment Environment - Investment in the AI healthcare sector peaked in 2021 with a total financing amount of 97.41 billion yuan and 380 financing events, but saw a decline in 2022 due to various global challenges [10][8] - The financing rounds for AI healthcare in China are primarily concentrated in early stages, with a shift towards later rounds as investors seek more certainty [12] Smart Hospital Information Technology Applications - New application technologies in hospitals, such as outpatient dispensing machines and AI in medical imaging, show significant regional disparities, with developed areas exhibiting over twice the application rates compared to less developed regions [14][15] - The integration of AI in hospital information systems is expected to increase, with software and service investments likely to rise as digital infrastructure improves [24] Automated Pharmacy Market - The penetration rate of automated pharmacies in China is currently low, but there is substantial potential for growth as healthcare infrastructure expands and AI technologies are further integrated [20][21] - Leading companies in the automated pharmacy sector are leveraging diverse product offerings and channel expansion to maintain market positions [26] Company Comparisons in Hospital Information Technology - The report provides a comparative analysis of key players in the hospital information technology sector, highlighting their strengths and areas of focus, such as Weining Health's comprehensive solutions in HIS systems and AI [24] Company Comparisons in Automated Pharmacy - A competitive landscape analysis of automated pharmacy companies reveals varying strengths, with companies like Jianhui Information and Ailong Technology leading in integrated solutions and market presence [26]

二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第7号一一回购股份》的相关 规定，公司在回购股份期间，应于每个月的前3个交易日内公告截至上月末的回购进展情况，现将公司 回购股份进展情况公告如下： 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 2025年4月25日，苏州艾隆科技股份有限公司（以下简称"公司"）召开第五届董事会第五次会议，审议 通过了《关于以集中竞价交易方式回购公司股份的议案》，同意公司以自有资金通过上海证券交易所交 易系统以集中竞价交易方式回购公司已发行的部分人民币普通股（A股）股票，回购的股份将全部用于 员工持股计划或股权激励，回购价格不超过人民币23.20元/股，回购资金总额不低于150万元（含）， 不超过人民币300万元（含）。回购期限自董事会审议通过本次回购方案之日起12个月内。 具体情况详见公司于2025年4月29日在上海证券交易所网站（www.sse.com.cn）披 ...

证券日报网讯12月1日，艾隆科技在互动平台回答投资者提问时表示，截至2025年11月30日，公司股东 持有人数(已合并)4916户。 ...

Company Summary - Elon Technology (SH 688329) announced a share buyback of approximately 56,000 shares, representing 0.0725% of the total share capital, with a total expenditure of around RMB 1.12 million [1][1][1] - The highest buyback price was RMB 20.37 per share, while the lowest was RMB 19.75 per share [1][1][1] - As of the report, Elon Technology has a market capitalization of RMB 1.7 billion [1][1][1] Revenue Composition - For the year 2024, the revenue composition of Elon Technology is as follows: 91.73% from the manufacturing of other specialized equipment and 8.27% from other business activities [1][1][1]

苏州艾隆科技股份有限公司 证券代码：688329 证券简称：艾隆科技 公告编号：2025-056 关于以集中竞价交易方式回购公司股份 的回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/29 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 月 年 月 2025 4 4 | 25 | 日~2026 | 24 | 日 | | 预计回购金额 | 150 万元~300 万元 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 5.6 万股 | | | | | | 累计已回购股数占总股本比 | 0.0725% | | | | | | 例 | | | | | | | 累计已回购金额 | 万元 111.656 | | | | | | 实际回购价 ...